Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre

European Journal of Endocrinology

Volumn 145, Issue 2, 2001, Pages 137-145

  Abe, T ^a   Ludecke D K ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ACROMEGALY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MICROADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL APPROACH; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0034894477     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1450137     Document Type: Article

References (33)

1. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
2. Octreotide treatment of acromegaly. A randomized, multicenter study
3. Recent advances in pathogenesis, diagnosis and management of acromegaly
4. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
5. Octreotide as primary therapy for acromegaly
6. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients
7. Presurgical octreotide treatment in acromegaly
8. Presurgical octreotide: Treatment in acromegaly
9. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
10. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide
11. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate
12. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery
13. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly
14. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegaly patients
15. A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism
16. Acromegaly - The place of the neurosurgeon
17. Preoperative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observation
18. Effect of octreotide pretreatment on surgical outcome in acromegaly
19. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared with those in untreated matched controls
20. Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study
21. Value of transcavernous surgery in the treatment of pituitary adenomas
22. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings
23. Recent results of secondary transnasal surgery for residual or recurring acromegaly
24. Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly
25. Intraoperative GH measurement in acromegaly
26. Pressure-irrigation-suction system. Technical note
27. Effects of octreotide on morphology of pituitary adenomas in acromegaly. Pathology
28. Preoperative treatment of acromegaly with SMS 201-995: Surgical and pathological observations
29. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
30. Sandostatin LAR in acromegalic patients: A dose-range study
31. Sandostatin LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients
32. How many surgeons to operate on acromegalic patients?